Myeloproliferative Neoplasms (MPN) Overview

Save information for later
Sign Up

Learn About Myeloproliferative Neoplasms (MPN)

What is the definition of Myeloproliferative Neoplasms (MPN)?
Myeloproliferative neoplasms are rare blood cancers caused by the body making too many red blood cells, white blood cells, or platelets. There are several types of myeloproliferative neoplasms, including chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia.
What are the symptoms of Myeloproliferative Neoplasms (MPN)?
Symptoms of myeloproliferative neoplasms may not appear for years. Symptoms of myeloproliferative neoplasms depend on the type. The most common symptom is discomfort or pressure on the left side below the ribs due to an enlarged spleen. Other symptoms may include bone pain; night sweats; fever; fatigue; bruising easily; loss of appetite; unexplained weight loss; unexplained bleeding; blood in the urine; headaches; dizziness; blurred or double vision; pale or itchy skin; abdominal fullness; reddened face; weakness; shortness of breath; hearing problems; cough; swelling of the face, throat, hands or feet; muscle pain; and diarrhea.
Not sure about your diagnosis?
Check Your Symptoms
What are the different types of Myeloproliferative Neoplasms (MPN)?

Common conditions include: Myelofibrosis

What are the current treatments for Myeloproliferative Neoplasms (MPN)?
There is currently no cure for myeloproliferative neoplasms. Treatment for myeloproliferative neoplasms is focused on relieving the symptoms and preventing complications. Treatments for myeloproliferative neoplasms include watchful waiting, phlebotomy, platelet apheresis, transfusion therapy, chemotherapy, radiation therapy, drug therapy, immunotherapy, targeted therapy, chemotherapy, and stem cell transplant.
Who are the top Myeloproliferative Neoplasms (MPN) Local Doctors?
Distinguished in Myeloproliferative Neoplasms (MPN)
Dr. Ranjith Dissanayake
Hematology Oncology | Hematology | Oncology
Distinguished in Myeloproliferative Neoplasms (MPN)
Dr. Ranjith Dissanayake
Hematology Oncology | Hematology | Oncology

Sacred Heart Health System Inc

4501 N Davis Hwy, Suite C, 
Pensacola, FL 
 (96.2 mi)
850-416-4960
Languages Spoken:
English
See accepted insurances

Ranjith Dissanayake is a Hematologist Oncology specialist and a Hematologist in Pensacola, Florida. Dr. Dissanayake and is rated as a Distinguished provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Thrombocytopenia, Paget Disease of the Breast, and Bone Marrow Aspiration.

Advanced in Myeloproliferative Neoplasms (MPN)
Dr. Harish K. Malhotra
Oncology | Hematology | Hematology Oncology
Advanced in Myeloproliferative Neoplasms (MPN)
Dr. Harish K. Malhotra
Oncology | Hematology | Hematology Oncology
1545 Airport Blvd, Suite 2000, 
Pensacola, FL 
 (95.4 mi)
850-416-6933
Languages Spoken:
English

Harish Malhotra is an Oncologist and a Hematologist in Pensacola, Florida. Dr. Malhotra and is rated as an Advanced provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Multiple Myeloma, Sickle Cell Disease, Pleuropulmonary Blastoma, and Prostate Cancer.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Myeloproliferative Neoplasms (MPN)
Dr. Mose S. Hayes
Hematology Oncology | Oncology | Hematology
Advanced in Myeloproliferative Neoplasms (MPN)
Dr. Mose S. Hayes
Hematology Oncology | Oncology | Hematology

Sacred Heart Health System Inc

1545 Airport Blvd, 
Pensacola, FL 
 (95.4 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mose Hayes is a Hematologist Oncology specialist and an Oncologist in Pensacola, Florida. Dr. Hayes and is rated as an Advanced provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Hypersplenism, Paget Disease of the Breast, Colorectal Cancer, and Lynch Syndrome. Dr. Hayes is currently accepting new patients.

View All Doctors
What are the latest Myeloproliferative Neoplasms (MPN) Clinical Trials?
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Enrollment Status: Recruiting
Publish Date: February 17, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Enrollment Status: Recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.

View All Clinical Trials